Usefulness of the 2005 International Society of Urologic Pathology Gleason grading system in prostate biopsy and radical prostatectomy specimens
- PMID: 19076142
- DOI: 10.1111/j.1464-410X.2008.08197.x
Usefulness of the 2005 International Society of Urologic Pathology Gleason grading system in prostate biopsy and radical prostatectomy specimens
Abstract
Objective: To determine whether the 2005 International Society of Urologic Pathology (ISUP) Gleason Grading Consensus is clinically more useful than the conventional Gleason score (CGS), we compared the CGS and ISUP GS (IGS) of prostate needle biopsy (NB) and radical prostatectomy (RP) specimens, and evaluated the prognostic value of the ISUP GS.
Patients and methods: Of 250 patients undergoing RP, 103 with clinical stage T1-2 N0M0 were enrolled. Pathological tumour grades of NB and RP specimens were classified according to CGS by experienced pathologists in the central pathology department of our hospital, and retrospectively according to IGS by one uropathologist at the central pathology department of another hospital. All patients had RP with no neoadjuvant or adjuvant therapy. We analysed associations of CGS and IGS with biochemical recurrence-free survival (BRFS) after RP.
Results: The concordance rates between NB and RP specimens by CGS and IGS were 64.1% and 69.9%. Under-grading and over-grading rates by CGS and IGS were 28.2% and 7.8% for NB, and 27.2% and 2.9% for RP, respectively. There was a significant difference in the over-grading rate between CGS and IGS (P = 0.026). When CGS and IGS of NB and RP specimens were compared, the concordance rates were similar, at 67% and 69.9%. The IGS was higher, by 15.6% in NB and by 20.4% in RP specimens, than CGS. Patients were divided into three groups based on IGS of NB specimens (< or =6, 7 and > or =8). These groups differed significantly in BRFS after RP (P = 0.022); CGS showed no such association.
Conclusions: The IGS of NB specimens were significantly associated with BRFS after RP. The ISUP system is thus clinically useful for determining the most appropriate treatments for patients with early-stage prostate cancer.
Comment in
-
Usefulness of the 2005 International Society of Urological Pathology Gleason Grading System in prostate biopsy and radical prostatectomy specimens.BJU Int. 2009 Sep;104(5):722-3. doi: 10.1111/j.1464-410X.2009.08828_2.x. BJU Int. 2009. PMID: 19689580 No abstract available.
Similar articles
-
Prostate cancer grading: the effect of stratification of needle biopsy Gleason Score 4 + 3 as high or intermediate grade.BJU Int. 2010 Mar;105(5):631-5. doi: 10.1111/j.1464-410X.2009.08810.x. Epub 2009 Sep 3. BJU Int. 2010. PMID: 19732053
-
Concordance between Gleason scores of needle biopsies and radical prostatectomy specimens: a population-based study.BJU Int. 2009 Jun;103(12):1647-54. doi: 10.1111/j.1464-410X.2008.08255.x. Epub 2008 Dec 22. BJU Int. 2009. PMID: 19154461
-
Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy.Eur Urol. 2008 Apr;53(4):767-75; discussion 775-6. doi: 10.1016/j.eururo.2007.11.016. Epub 2007 Nov 20. Eur Urol. 2008. PMID: 18060681
-
The impact of the 2005 international society of urological pathology consensus conference on standard Gleason grading of prostatic carcinoma in needle biopsies.J Urol. 2008 Aug;180(2):548-52; discussion 552-3. doi: 10.1016/j.juro.2008.04.018. Epub 2008 Jun 11. J Urol. 2008. PMID: 18550106
-
Gleason grading of prostate cancer in needle biopsies or radical prostatectomy specimens: contemporary approach, current clinical significance and sources of pathology discrepancies.BJU Int. 2005 Jun;95(8):1146-52. doi: 10.1111/j.1464-410X.2005.05540.x. BJU Int. 2005. PMID: 15877724 Review.
Cited by
-
Prognostic Utility of the Gleason Grading System Revisions and Histopathological Factors Beyond Gleason Grade.Clin Epidemiol. 2022 Jan 18;14:59-70. doi: 10.2147/CLEP.S339140. eCollection 2022. Clin Epidemiol. 2022. PMID: 35082531 Free PMC article.
-
[Documentation quality of histopathology reports of prostate needle biopsies: a snapshot].Urologe A. 2014 Nov;53(11):1644-50. doi: 10.1007/s00120-014-3584-3. Urologe A. 2014. PMID: 25272987 German.
-
Biomarker research in prostate cancer--towards utility, not futility.Nat Rev Urol. 2011 Mar;8(3):131-8. doi: 10.1038/nrurol.2011.11. Nat Rev Urol. 2011. PMID: 21394176 Review.
-
The evolving Gleason grading system.Chin J Cancer Res. 2016 Feb;28(1):58-64. doi: 10.3978/j.issn.1000-9604.2016.02.04. Chin J Cancer Res. 2016. PMID: 27041927 Free PMC article. Review.
-
Validation of the WHO 2016 new Gleason score of prostatic carcinoma.Urol Ann. 2018 Jul-Sep;10(3):324-329. doi: 10.4103/UA.UA_185_17. Urol Ann. 2018. PMID: 30089994 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical